To evaluate the safety and efficacy of SurVaxM in combination with temozolomide in patients with progressing metastatic neuroendocrine tumors (NETs).
Key Findings:
SurVaxM is a peptide vaccine targeting the protein survivin, which is expressed in approximately 52% of NET specimens.
Phase 1 study showed SurVaxM was well tolerated and generated measurable immune responses.
The incidence of NETs has increased significantly, with about 28,000 new cases diagnosed annually in the U.S.
Interpretation:
The trial aims to provide new treatment options for NET patients, particularly those with limited therapies after first-line treatment.
Limitations:
The trial's outcomes are yet to be determined as it is in the early stages.
Immunotherapy has shown limited efficacy in NETs historically.
Conclusion:
The phase 2 trial represents a significant step in exploring new immunologic targets for treating metastatic NETs, building on promising phase 1 results.
